Pfizer essentially confirming Omicron is mild = Omicron needs to be “repriced” in financial markets
Pfizer’s CEO, Albert Bourla, told the WSJ yesterday that Omicron does appear milder and this is another positive anecdote.

  • Symptoms from Omicron appearing milder
  • This is consistent with many health experts who have argued virus gain transmissibility but trade-off tends to be lethality
  • This is still not clinically proven, so this remains another “incoming anecdote”
The video in this report is only accessible to members

But equity markets and consumers (based on google trends) perceive far more severe risk from Omicron. Thus, to the extent that Omicron proves to be milder, the more likely it is we see markets levitate.

  • we published this exhibit on Sunday
  • and the point is that we think there is a 95% chance Omicron is “less bad” than markets believe
  • incremental data supporting “less bad” would lead to equity markets gaining
The video in this report is only accessible to members
…Daily deaths in South Africa are not increasing = good signCOVID-19 remains unpredictable, so take our comments with a grain of salt. Our data science team, led by tireless Ken, has highlighted d...

Unlock this article with a FREE 30-Day Trial!

An FSI Pro, or FSI Macro subscription is required in order to access this content.

*Free trial available only on a monthly plan

More from the author

Disclosures (show)

Get invaluable analysis of the market and stocks. Cancel at any time. Start Free Trial

Articles Read 2/2

🎁 Unlock 1 extra article by joining our Community!

You’ve reached your limit of 2 free monthly articles. Please enter your email to unlock 1 more articles.

Already have an account? Sign In

Want to receive Regular Market Updates to your Inbox?

I am your default error :)